These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 23504176

  • 21. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.
    El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Foley J, Holmes D, Nauck MA.
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4165-71. PubMed ID: 17698900
    [Abstract] [Full Text] [Related]

  • 22. Vildagliptin ameliorates pulmonary fibrosis in lipopolysaccharide-induced lung injury by inhibiting endothelial-to-mesenchymal transition.
    Suzuki T, Tada Y, Gladson S, Nishimura R, Shimomura I, Karasawa S, Tatsumi K, West J.
    Respir Res; 2017 Oct 16; 18(1):177. PubMed ID: 29037205
    [Abstract] [Full Text] [Related]

  • 23. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats.
    Jin HY, Liu WJ, Park JH, Baek HS, Park TS.
    Arch Med Res; 2009 Oct 16; 40(7):536-44. PubMed ID: 20082866
    [Abstract] [Full Text] [Related]

  • 24. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients.
    Boschmann M, Engeli S, Dobberstein K, Budziarek P, Strauss A, Boehnke J, Sweep FC, Luft FC, He Y, Foley JE, Jordan J.
    J Clin Endocrinol Metab; 2009 Mar 16; 94(3):846-52. PubMed ID: 19088168
    [Abstract] [Full Text] [Related]

  • 25. Dipeptidyl peptidase 4 inhibitor reduces intimal hyperplasia in rabbit autologous jugular vein graft under poor distal runoff.
    Koyama A, Komori K, Otsuka R, Kajikuri J, Itoh T.
    J Vasc Surg; 2016 May 16; 63(5):1360-70. PubMed ID: 25656593
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes.
    Akarte AS, Srinivasan BP, Gandhi S.
    J Diabetes Complications; 2012 May 16; 26(4):266-74. PubMed ID: 22626875
    [Abstract] [Full Text] [Related]

  • 28. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism.
    Ahrén B, Foley JE.
    Int J Clin Pract Suppl; 2008 Mar 16; (159):8-14. PubMed ID: 18269436
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs.
    Hjøllund KR, Deacon CF, Holst JJ.
    Diabetologia; 2011 Aug 16; 54(8):2206-8. PubMed ID: 21604085
    [No Abstract] [Full Text] [Related]

  • 31. DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice.
    Shimizu S, Hosooka T, Matsuda T, Asahara S, Koyanagi-Kimura M, Kanno A, Bartolome A, Etoh H, Fuchita M, Teruyama K, Takahashi H, Inoue H, Mieda Y, Hashimoto N, Seino S, Kido Y.
    J Mol Endocrinol; 2012 Oct 16; 49(2):125-35. PubMed ID: 22822047
    [Abstract] [Full Text] [Related]

  • 32. Impact of Either GLP-1 Agonists or DPP-4 Inhibitors on Pathophysiology of Heart Failure.
    Takahashi A, Ihara M, Yamazaki S, Asanuma H, Asakura M, Kitakaze M.
    Int Heart J; 2015 Oct 16; 56(4):372-6. PubMed ID: 26104180
    [Abstract] [Full Text] [Related]

  • 33. The scientific evidence: vildagliptin and the benefits of islet enhancement.
    Mathieu C.
    Diabetes Obes Metab; 2009 May 16; 11 Suppl 2():9-17. PubMed ID: 19385979
    [Abstract] [Full Text] [Related]

  • 34. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice.
    Flock G, Baggio LL, Longuet C, Drucker DJ.
    Diabetes; 2007 Dec 16; 56(12):3006-13. PubMed ID: 17717280
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes.
    He YL, Yamaguchi M, Ito H, Terao S, Sekiguchi K.
    Int J Clin Pharmacol Ther; 2010 Sep 16; 48(9):582-95. PubMed ID: 20860912
    [Abstract] [Full Text] [Related]

  • 38. Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate.
    Lee DS, Lee ES, Alam MM, Jang JH, Lee HS, Oh H, Kim YC, Manzoor Z, Koh YS, Kang DG, Lee DH.
    Metabolism; 2016 Feb 16; 65(2):89-101. PubMed ID: 26773932
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.